Breaking up is hard to do, but not for Exact Sciences (NASDAQ: EXAS) and Pfizer (NYSE: PFE). Recently the partners let a partnership that was a lot more important to the diagnostics provider than the pharmaceutical giant come to an abrupt end. Shares of Exact Sciences soared in 2020, but the stock has been under a lot of pressure this year.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting